PDCD1 and neoplasm: Gene expression profiling is commonly used to investigate the immune profiles of the tumour microenvironment for cancer patients, particularly in the setting of response and survival predictions for cancer patients treated with anti-PD-1 monotherapy and anti-PD-1 + anti-CTLA-4 therapy [1–4].